Phase 3 Hypercholesterolaemia Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Hypercholesterolaemiamixed dyslipidemia
A. Menarini International Licensing S.A.426 enrolled1 locationNCT07614958
Recruiting
Phase 3
efficacy of LOw dose antihypertensive and lipid lowering pill combinations To improve stroke oUtcomeS (LOTUS)
HypercholesterolaemiaHypertensionTransient Ischaemic Attack+1 more
The George Institute for Global Health Australia400 enrolled19 locationsACTRN12624001279516
Recruiting
Phase 3
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.582 enrolled1 locationNCT05621070
Terminated
Phase 3
Evaluating the efficacy and adherence of administration of a PCSK9 inhibitor Alirocumab in Aboriginal participants with hypercholesterolaemia
Hypercholesterolaemia
South Australian Health and Medical Research Institute200 enrolled3 locationsACTRN12616000871448
Completed
Phase 3
Dose Response Study of a Complementary Medicine Formulation in Primary Hypercholesterolaemia
Primary Hypercholesterolaemia
Pathways40 enrolled1 locationACTRN12605000232639